Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | AOC3 | Q16853 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6320678 | 0.87 | KDM4E (0.57) | KDM4EMEN1KMT2ASMN1; SMN2AOC3 | |
| SCHEMBL4753451 | 0.83 | KDM4E (0.49) | KDM4EMEN1KMT2ASMN1; SMN2AOC3 | |
| SCHEMBL4583626 | 0.82 | AOC3 (0.61) | KDM4EMEN1KMT2ASMN1; SMN2AOC3 | |
| SCHEMBL20660983 | 0.81 | AOC3 (0.62) | KDM4EMEN1KMT2ASMN1; SMN2AOC3 | |
| SCHEMBL6318439 | 0.81 | MEN1 (0.52) | KDM4EMEN1KMT2ASMN1; SMN2AOC3 | |
| SCHEMBL6320187 | 0.80 | AOC3 (0.46) | KDM4EMEN1KMT2ASMN1; SMN2AOC3 | |
| SCHEMBL6666186 | 0.79 | PPARG (0.40) | KDM4EMEN1KMT2ASMN1; SMN2AOC3 | |
| SCHEMBL6319749 | 0.79 | KDM4E (0.46) | KDM4EMEN1KMT2ASMN1; SMN2AOC3 | |
| SCHEMBL6320185 | 0.77 | AOC3 (0.46) | KDM4EMEN1KMT2ASMN1; SMN2AOC3 | |
| SCHEMBL1935803 | 0.76 | RAB9A (0.52) | MEN1KMT2ASMN1; SMN2ALDH1A1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6852731-B2 | Antiviral compounds | PFIZER (US) | 2005-02-08 | — | — | US | disclosed |
| US-20040242884-A1 | ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY | 2004-12-02 | — | — | US | disclosed |
| EP-1472260-A2 | THIENO(3,2-B)PYRIDONES AS ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040116464-A1 | Aryl-ethanolamine derivatives as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2004-06-17 | — | — | US | disclosed |
| WO-2003059878-A2 | THIENO (3, 2-B) PYRIDONES AS ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242884-A1 | ANTIVIRAL COMPOUNDS | ZC3HAV1, IRF3, IFNAR1 | KDM4E 1156/4885MEN1 1462/4885KMT2A 2402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.